HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) and maintained a $1 price target.
August 19, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Neutral rating on Lyell Immunopharma and maintained a $1 price target.
The reiteration of a Neutral rating and maintenance of a $1 price target suggests that the analyst does not foresee significant short-term movement in the stock price. This neutral stance indicates a balanced view of the company's prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100